176 related articles for article (PubMed ID: 21785998)
1. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN
Invest New Drugs; 2012 Aug; 30(4):1652-9. PubMed ID: 21785998
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
6. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Azad AA; Beardsley EK; Hotte SJ; Ellard SL; Klotz L; Chin J; Kollmannsberger C; Mukherjee SD; Chi KN
Invest New Drugs; 2014 Aug; 32(4):746-52. PubMed ID: 24671507
[TBL] [Abstract][Full Text] [Related]
9. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
10. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
13. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Steinbild S; Mross K; Frost A; Morant R; Gillessen S; Dittrich C; Strumberg D; Hochhaus A; Hanauske AR; Edler L; Burkholder I; Scheulen M
Br J Cancer; 2007 Dec; 97(11):1480-5. PubMed ID: 18040273
[TBL] [Abstract][Full Text] [Related]
14. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
16. About sorafenib in castration-resistant prostate cancer.
Colloca G; Checcaglini F; Venturino A
Ann Oncol; 2008 Oct; 19(10):1812-3; author reply 1813-1814. PubMed ID: 18689865
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.
Safarinejad MR
Urol Oncol; 2010; 28(1):21-7. PubMed ID: 18789732
[TBL] [Abstract][Full Text] [Related]
19. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]